Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders

Genetics in Medicine

Volumn 10, Issue 12, 2008, Pages 851-868

  Moskowitz, Samuel M ^a   Chmiel, James F ^b   Sternen, Darci L ^c   Cheng, Edith ^a   Gibson, Ronald L ^a   Marshall, Susan G ^a   Cutting, Garry R ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CFTR; Congenital absence of vas deferens; Cystic fibrosis; Diagnostic testing; Genetic counseling

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CALCIUM; CHLORIDE; CORTICOSTEROID; DORNASE ALFA; HUMAN GROWTH HORMONE; INFLUENZA VACCINE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PALIVIZUMAB; PNEUMOCOCCUS VACCINE; SODIUM CHLORIDE; STEROID; TRYPSINOGEN; VITAMIN; VITAMIN D; ZINC;

AGENESIS; ARTHRITIS; AZOOSPERMIA; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SURVEILLANCE; ENZYME REPLACEMENT; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC DISORDER; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; IMMUNIZATION; KINESIOTHERAPY; LUNG DISEASE; MOLECULAR GENETICS; NOSE DISEASE; OSTEOPENIA; PANCREAS INSUFFICIENCY; PARANASAL SINUS DISEASE; PATHOGENESIS; PNEUMOCOCCAL INFECTION; POSTURAL DRAINAGE; PRENATAL DIAGNOSIS; PREVALENCE; PROPHYLAXIS; RESPIRATORY TRACT INFECTION; REVIEW; SEMEN ANALYSIS; STREPTOCOCCUS PNEUMONIA; SWEAT; VAS DEFERENS; VIRUS INFECTION;

ALLELES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA MUTATIONAL ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIATION; GENOTYPE; HUMANS; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 58149215722     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31818e55a2     Document Type: Review

References (118)

1. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-595.
2. Hamosh A, FitzSimmons SC, Macek M Jr, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998;132:255-259.
3. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test 1997;1:35-39.
4. Casals T, Bassas L, Egozcue S, et al. Heterogeneity for mutations in the CFTR gene and clinical correlations in patients with congenital absence of the vas deferens. Hum Reprod 2000;15:1476-1483.
5. Moskowitz SM, Gibson RL, Effmann EL. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatr Radiol 2005;35:739-757.
6. Tsui L-C, Zielenski J. Cystic Fibrosis Mutation Database. 2007. Available at: http://www.genet.sickkids.on.ca/cftr/app. Accessed November 4, 2008.
7. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387-391.
8. Alper OM, Wong LJ, Young S, et al. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. Hum Mutat 2004;24:353.
9. Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 2006;131:1030-1039.
10. De Braekeleer M, Allard C, Leblanc JP, Simard F, Aubin G. Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation. Hum Genet 1997;101:208-211.
11. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-1453.
12. Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007;175:1036-1043.
13. Braun AT, Farrell PM, Ferec C, et al. Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. J Cyst Fibros 2006;5:33-41.
14. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005;6:237-260.
15. Goss CH, Newsom SA, Schildcrout JS, Sheppard L, Kaufman JD. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med 2004;169:816-821.
16. Cystic Fibrosis Foundation. CFF Patient Registry, Bethesda, Maryland, 2008.
17. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794-803.
18. Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest 2005;128:2824-2834.
19. Cystic Fibrosis Foundation. CFF Patient Registry, Bethesda, Maryland, 2006.
20. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-577.
21. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004;144:154-161.
22. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23:93-97.
23. Dray X, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, Hubert D. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2004;2:498-503.
24. Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992;120:533-540.
25. De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics 2005;115:e463-e469.
26. Cystic Fibrosis Foundation. CFF Patient Registry, Bethesda, Maryland, 2005.
27. Hardin DS, LeBlanc A, Lukenbough S, Seilheimer DK. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr 1997;130:948-956.
28. Lanng S. Diabetes mellitus in cystic fibrosis. Eur J Gastroenterol Hepatol 1996;8:744-747.
29. Koch C, Rainisio M, Madessani U, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001;32:343-350.
30. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005;28:2141-2144.
31. Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33:483-491.
32. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006;29:2660-2663.
33. Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30:1056-1061.
34. van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008;7:515-519.
35. Cystic Fibrosis Foundation. CFF Patient Registry, Bethesda, Maryland, 2003.
36. Edenborough FP, Mackenzie WE, Stableforth DE. The outcome of 72 pregnancies in 55 women with cystic fibrosis in the United Kingdom 1977-1996. BJOG 2000;107:254-261.
37. Gilljam M, Antoniou M, Shin J, Dupuis A, Corey M, Tullis DE. Pregnancy in cystic fibrosis. Fetal and maternal outcome. Chest 2000;118:85-91.
38. Gillet D, de Braekeleer M, Bellis G, Durieu I. Cystic fibrosis and pregnancy. Report from French data (1980-1999). BJOG 2002;109:912-918.
39. Cheng EY, Goss CH, McKone EF, et al. Aggressive prenatal care results in successful fetal outcomes in CF women. J Cyst Fibros 2006;5:85-91.
40. Goss CH, Rubenfeld GD, Otto K, Aitken ML. The effect of pregnancy on survival in women with cystic fibrosis. Chest 2003;124:1460-1468.
41. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003;361:1671-1676.
42. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006;130:1441-1447.
43. Bremer LA, Blackman SM, Vanscoy LL, et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet 2008;17:2228-2237.
44. Kiesewetter S, Macek M Jr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993;5:274-278.
45. Massie RJ, Poplawski N, Wilcken B, Goldblatt J, Byrnes C, Robertson C. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001;17:1195-1200.
46. Chmiel JF, Drumm ML, Konstan MW, Ferkol TW, Kercsmar CM. Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis. Pediatrics 1999;103:823-826.
47. Dork T, Dworniczak B, Aulehla-Scholz C, et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 1997;100:365-377.
48. Gilljam M, Moltyaner Y, Downey GP, et al. Airway inflammation and infection in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 2004;169:174-179.
49. Noone PG, Pue CA, Zhou Z, et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 2000;162:1919-1924.
50. Cuppens H, Lin W, Jaspers M, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 1998;101:487-496.
51. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004;74:176-179.
52. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004;169:459-467.
53. Marthinsen L, Kornfalt R, Aili M, Andersson D, Westgren U, Schaedel C. Recurrent Pseudomonas bronchopneumonia and other symptoms as in cystic fibrosis in a child with type I pseudohypoaldosteronism. Acta Paediatr 1998;87:472-474.
54. Schaedel C, Marthinsen L, Kristoffersson AC, et al. Lung symptoms in pseudohypoaldosteronism type 1 are associated with deficiency of the alpha-subunit of the epithelial sodium channel. J Pediatr 1999;135:739-745.
55. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med 2002;347:401-407.
56. Sheridan MB, Fong P, Groman JD, et al. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet 2005;14:3493-3498.
57. Mak V, Zielenski J, Tsui LC, et al. Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. JAMA 1999;281:2217-2224.
58. Comeau AM, Accurso FJ, White TB, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007;119:e495-e518.
59. LeGrys VA. Sweat testing for the diagnosis of cystic fibrosis: practical considerations. J Pediatr 1996;129:892-897.
60. LeGrys VA, Rosenstein BJ, Doumas BT, et al. Sweat testing: sample collection and quantitative analysis; approved guideline [Document C34-A2], 2nd ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
61. Farrell PM, Koscik RE. Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. Pediatrics 1996;97:524-528.
62. Schuler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004;3(suppl 2):151-155.
63. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004;37:385-392.
64. Wagener JS, Sontag MK, Sagel SD, Accurso FJ. Update on newborn screening for cystic fibrosis. Curr Opin Pulm Med 2004;10:500-504.
65. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 2006;149:362-366.
66. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 2005;147:S83-S88.
67. Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics 1997;99:819-824.
68. Pollitt R. Neonatal screening for cystic fibrosis. Early diagnosis is important to parents even if it makes little difference to outcome. BMJ 1998;317:411-412.
69. Wilcken B, Wiley V. Newborn screening methods for cystic fibrosis. Paediatr Respir Rev 2003;4:272-277.
70. Holsclaw DS, Perlmutter AD, Jockin H, Shwachman H. Genital abnormalities in male patients with cystic fibrosis. J Urol 1971;106:568-574.
71. Richards CS, Bradley LA, Amos J, et al. Standards and guidelines for CFTR mutation testing. Genet Med 2002;4:379-391.
72. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-156.
73. Strom CM, Huang D, Chen C, et al. Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test. Genet Med 2003;5:9-14.
74. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339:653-658.
75. Luisetti M, Gile LS, Bombieri C, Benetazzo MG, Pignatti PF. Genetics of chronic obstructive pulmonary disease and disseminated bronchiectasis. Monaldi Arch Chest Dis 1998;53:614-616.
76. Mickle JE, Cutting GR. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin Chest Med 1998;19:443-458, v.
77. Wang X, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-1819.
78. Cohn JA, Mitchell RM, Jowell PS. The role of cystic fibrosis gene mutations in determining susceptibility to chronic pancreatitis. Gastroenterol Clin North Am 2004;33:817-837, vii.
79. Cohn JA, Neoptolemos JP, Feng J, et al. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat 2005;26:303-307.
80. Weiss FU, Simon P, Bogdanova N, et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005;54:1456-1460.
81. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
82. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
83. Bradley JM, Moran FM, Elborn JS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med 2006;100:191-201.
84. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2005:CD004730.
85. Allen HF, Gay EC, Klingensmith GJ, Hamman RF. Identification and treatment of cystic fibrosis-related diabetes. A survey of current medical practice in the U.S. Diabetes Care 1998;21:943-948.
86. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999;45:61-73.
87. Gyi KM, Hodson ME, Yacoub MY. Pregnancy in cystic fibrosis lung transplant recipients: case series and review. J Cyst Fibros 2006;5:171-175.
88. Smith JL, Lewindon PJ, Hoskins AC, et al. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology 2004;39:1673-1682.
89. Nousia-Arvanitakis S, Fotoulaki M, Economou H, Xefteri M, Galli-Tsinopoulou A. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001;32:324-328.
90. Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr Treat Options Gastroenterol 2006;9:484-496.
91. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250.
92. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240.
93. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
94. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-623.
95. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849.
96. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985;1:865.
97. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002;140:299-305.
98. Kerem E. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Pediatr Pulmonol 2005;40:183-196.
99. Rubenstein RC. Novel, mechanism-based therapies for cystic fibrosis. Curr Opin Pediatr 2005;17:385-392.
100. Verkman AS, Lukacs GL, Galietta LJ. CFTR chloride channel drug discovery - inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr Pharm Des 2006;12:2235-2247.
101. Anson DS, Smith GJ, Parsons DW. Gene therapy for cystic fibrosis airway disease - is clinical success imminent? Curr Gene Ther 2006;6:161-179.
102. Grody WW. Cystic fibrosis: molecular diagnosis, population screening, and public policy. Arch Pathol Lab Med 1999;123:1041-1046.
103. Lagoe E, Labella S, Arnold G, Rowley PT. Cystic fibrosis newborn screening: a pilot study to maximize carrier screening. Genet Test 2005;9:255-260.
104. Girodon-Boulandet E, Cazeneuve C, Goossens M. Screening practices for mutations in the CFTR gene ABCC7. Hum Mutat 2000;15:135-149.
105. Corteville JE, Gray DL, Langer JC. Bowel abnormalities in the fetus - correlation of prenatal ultrasonographic findings with outcome. Am J Obstet Gynecol 1996;175:724-729.
106. Ghose I, Mason GC, Martinez D, et al. Hyperechogenic fetal bowel: a prospective analysis of sixty consecutive cases. BJOG 2000;107:426-429.
107. Slotnick RN, Abuhamad AZ. Prognostic implications of fetal echogenic bowel. Lancet 1996;347:85-87.
108. Bosco AF, Norton ME, Lieberman E. Predicting the risk of cystic fibrosis with echogenic fetal bowel and one cystic fibrosis mutation. Obstet Gynecol 1999;94:1020-1023.
109. Hodge SE, Lebo RV, Yesley AR, Cheney SM, Angle H, Milunsky J. Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation: avoiding pitfalls in the risk calculations. Am J Med Genet 1999;82:329-335.
110. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics Mutation panel. Genet Med 2004;6:387-391.
111. Wilson RD, Davies G, Desilets V, et al. Cystic fibrosis carrier testing in pregnancy in Canada. J Obstet Gynaecol Can 2002;24:644-651.
112. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995;29:777-807.
113. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008;7:179-196.
114. Witt DR, Schaefer C, Hallam P, et al. Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 1996;58:823-835.
115. Brock DJ, Gilfillan A, Holloway S. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies. Clin Genet 1998;53:47-49.
116. Wang X, Myers A, Saiki RK, Cutting GR. Development and evaluation of a PCR-based, line probe assay for the detection of 58 alleles in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Clin Chem 2002;48:1121-1123.
117. Grody WW, Cutting GR, Klinger KW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-154.
118. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med 2002;4:90-94.